Cargando…
Risk of Type 2 Diabetes Mellitus following Gestational Diabetes Pregnancy in Women with Polycystic Ovary Syndrome
BACKGROUND: This study examines gestational diabetes mellitus (GDM) in women with polycystic ovary syndrome (PCOS) and the risk of type 2 diabetes mellitus (DM) following GDM pregnancy. METHODS: A cohort of 988 pregnant women with PCOS who delivered during 2002–2005 was examined to determine the pre...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5750496/ https://www.ncbi.nlm.nih.gov/pubmed/29423416 http://dx.doi.org/10.1155/2017/5250162 |
_version_ | 1783289736297709568 |
---|---|
author | Lo, Joan C. Yang, Jingrong Gunderson, Erica P. Hararah, Mohammad K. Gonzalez, Joel R. Ferrara, Assiamira |
author_facet | Lo, Joan C. Yang, Jingrong Gunderson, Erica P. Hararah, Mohammad K. Gonzalez, Joel R. Ferrara, Assiamira |
author_sort | Lo, Joan C. |
collection | PubMed |
description | BACKGROUND: This study examines gestational diabetes mellitus (GDM) in women with polycystic ovary syndrome (PCOS) and the risk of type 2 diabetes mellitus (DM) following GDM pregnancy. METHODS: A cohort of 988 pregnant women with PCOS who delivered during 2002–2005 was examined to determine the prevalence and predictors of GDM, with follow-up through 2010 among those with GDM to estimate the risk of DM. RESULTS: Of the 988 pregnant women with PCOS, 192 (19%) developed GDM. Multivariable predictors of GDM included older age, Asian race, prepregnancy obesity, family history of DM, preconception metformin use, and multiple gestation. Among women with PCOS and GDM pregnancy, the incidence of DM was 2.8 (95% confidence interval (CI) 1.9–4.2) per 100 person-years and substantially higher for those who received pharmacologic treatment for GDM (6.6 versus 1.5 per 100 person-years, p < 0.01). The multivariable adjusted risk of DM was fourfold higher in women who received pharmacologic treatment for GDM (adjusted hazard ratio 4.1, 95% CI 1.8–9.6). The five-year incidence of DM was 13.1% overall and also higher in the pharmacologic treatment subgroup (27.0% versus 7.1%, p < 0.01). CONCLUSIONS: The strongest predictors of GDM among women with PCOS included Asian race and prepregnancy obesity. Pharmacologic treatment of GDM is associated with fourfold higher risk of subsequent DM. |
format | Online Article Text |
id | pubmed-5750496 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-57504962018-02-08 Risk of Type 2 Diabetes Mellitus following Gestational Diabetes Pregnancy in Women with Polycystic Ovary Syndrome Lo, Joan C. Yang, Jingrong Gunderson, Erica P. Hararah, Mohammad K. Gonzalez, Joel R. Ferrara, Assiamira J Diabetes Res Research Article BACKGROUND: This study examines gestational diabetes mellitus (GDM) in women with polycystic ovary syndrome (PCOS) and the risk of type 2 diabetes mellitus (DM) following GDM pregnancy. METHODS: A cohort of 988 pregnant women with PCOS who delivered during 2002–2005 was examined to determine the prevalence and predictors of GDM, with follow-up through 2010 among those with GDM to estimate the risk of DM. RESULTS: Of the 988 pregnant women with PCOS, 192 (19%) developed GDM. Multivariable predictors of GDM included older age, Asian race, prepregnancy obesity, family history of DM, preconception metformin use, and multiple gestation. Among women with PCOS and GDM pregnancy, the incidence of DM was 2.8 (95% confidence interval (CI) 1.9–4.2) per 100 person-years and substantially higher for those who received pharmacologic treatment for GDM (6.6 versus 1.5 per 100 person-years, p < 0.01). The multivariable adjusted risk of DM was fourfold higher in women who received pharmacologic treatment for GDM (adjusted hazard ratio 4.1, 95% CI 1.8–9.6). The five-year incidence of DM was 13.1% overall and also higher in the pharmacologic treatment subgroup (27.0% versus 7.1%, p < 0.01). CONCLUSIONS: The strongest predictors of GDM among women with PCOS included Asian race and prepregnancy obesity. Pharmacologic treatment of GDM is associated with fourfold higher risk of subsequent DM. Hindawi 2017 2017-12-20 /pmc/articles/PMC5750496/ /pubmed/29423416 http://dx.doi.org/10.1155/2017/5250162 Text en Copyright © 2017 Joan C. Lo et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Lo, Joan C. Yang, Jingrong Gunderson, Erica P. Hararah, Mohammad K. Gonzalez, Joel R. Ferrara, Assiamira Risk of Type 2 Diabetes Mellitus following Gestational Diabetes Pregnancy in Women with Polycystic Ovary Syndrome |
title | Risk of Type 2 Diabetes Mellitus following Gestational Diabetes Pregnancy in Women with Polycystic Ovary Syndrome |
title_full | Risk of Type 2 Diabetes Mellitus following Gestational Diabetes Pregnancy in Women with Polycystic Ovary Syndrome |
title_fullStr | Risk of Type 2 Diabetes Mellitus following Gestational Diabetes Pregnancy in Women with Polycystic Ovary Syndrome |
title_full_unstemmed | Risk of Type 2 Diabetes Mellitus following Gestational Diabetes Pregnancy in Women with Polycystic Ovary Syndrome |
title_short | Risk of Type 2 Diabetes Mellitus following Gestational Diabetes Pregnancy in Women with Polycystic Ovary Syndrome |
title_sort | risk of type 2 diabetes mellitus following gestational diabetes pregnancy in women with polycystic ovary syndrome |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5750496/ https://www.ncbi.nlm.nih.gov/pubmed/29423416 http://dx.doi.org/10.1155/2017/5250162 |
work_keys_str_mv | AT lojoanc riskoftype2diabetesmellitusfollowinggestationaldiabetespregnancyinwomenwithpolycysticovarysyndrome AT yangjingrong riskoftype2diabetesmellitusfollowinggestationaldiabetespregnancyinwomenwithpolycysticovarysyndrome AT gundersonericap riskoftype2diabetesmellitusfollowinggestationaldiabetespregnancyinwomenwithpolycysticovarysyndrome AT hararahmohammadk riskoftype2diabetesmellitusfollowinggestationaldiabetespregnancyinwomenwithpolycysticovarysyndrome AT gonzalezjoelr riskoftype2diabetesmellitusfollowinggestationaldiabetespregnancyinwomenwithpolycysticovarysyndrome AT ferraraassiamira riskoftype2diabetesmellitusfollowinggestationaldiabetespregnancyinwomenwithpolycysticovarysyndrome |